| Identification | Back Directory | [Name]
Otelixizumab | [CAS]
881191-44-2 | [Synonyms]
Otelixizumab
Otelixizumab (anti-CD3)
Research Grade Otelixizumab(DHC27702) |
| Hazard Information | Back Directory | [Uses]
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes[1]. | [in vivo]
Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice[1]. | Animal Model: | BALB/c-huCD3e mice carrying the human CD3e chain[1] | | Dosage: | 100 μg/mouse | | Administration: | Intravenous injection, once | | Result: | Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells. |
| [References]
[1] Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3(68):68ra10. DOI:10.1126/scitranslmed.3001830
[2] Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16(6):841-6. DOI:10.1080/14712598.2016.1180363 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|